REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce that it has executed an asset purchase agreement (“Agreement”) dated January 11, 2022, to acquire a Ketamine clinic located in Jacksonville, Florida (“Acquisition”). Revitalist had previously announced the Acquisition non-binding letter of intent on October 27, 2021. This Acquisition represents the ninth clinic for the Company and is expected to commence under the Revitalist brand by February 1, 2022. The Jacksonville clinic was formed in 2017 and continues to be managed by Dr. Nicholas Kalynych who has over 30 years of experience in health care.

Dr. Nicholas Kalynych commented: “I am very pleased to be teaming up with Revitalist to accelerate growth of the practice in Jacksonville. With this acquisition complete, we are now positioned to significantly expand our service offerings and patient count, which will provide the Jacksonville community greater access to care.”

Kathryn Walker, CEO of Revitalist, commented: “With the closing of this acquisition, Revitalist will have nine clinics operating in six states. We are well on our way to executing our growth plans. On behalf of the entire company, I would like to formally welcome Dr. Kalynych and his team to Revitalist. We look forward to implementing our business model in Jacksonville and utilizing the decades of experience provided by Dr. Kalynych to offer exceptional treatments to the community.”

Pursuant to the terms of the Agreement, the consideration for the Acquisition is $100,000 USD. The consideration payable is $60,000 USD in cash and $40,000 in common shares. The share consideration will be issued at the greater of $0.50/share and the 20-day volume weighted average share price preceding the issue date and will be issued 50% in 12 months and 50% in 24 months following the closing of the Acquisition.

ABOUT REVITALIST LIFESTYLE AND WELLNESS LTD.

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is a publicly traded company, headquartered in Knoxville, Tennessee, with seven clinics operating across the United States and expanding. Revitalist is dedicated to empowering individuals toward an improved quality of well-being through a combination of comprehensive care and future-centric treatments provided by medical professionals, mental health experts, and chronic pain specialists. Since opening their first clinic in 2018, Revitalist has provided thousands of infusions for patients suffering from treatment-resistant conditions. Additionally, Revitalist offers a number of lifestyle optimization services and vitamin infusions that can bring anyone closer to total wellness. For additional information and to be added to the Company’s mailing list, please click here .

Twitter: @RevitalistCorp
Facebook: @RevitalistLifestyleandWellnessLtd.
Instagram: @RevitalistCorp
LinkedIn: @RevitalistLifestyleAndWellnessLtd

On Behalf of the Board:
Kathryn Walker
Chief Executive Officer

Forward Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Revitalist to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.

Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005347/en/

For further information:
Revitalist Lifestyle and Wellness Ltd.
Email: [email protected]
Tel: (865) 585-8414

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

As the cannabis industry strives to gain widespread acceptance in the mainstream, scientific studies into the potential benefits of the plant and its active ingredients play a key role in reaching that goal. There are currently very few approved pharmaceutical drug applications for cannabinoids, but that could change. After decades of effective prohibition there is a growing body of research surrounding cannabinoids, and more drug approvals are likely to follow.

All of the above applies equally to the promising area of psychedelic research, though the psychedelic industry is at an even earlier stage than the cannabis industry. Studies point to potential benefits for patients suffering from conditions such as PTSD, anxiety, addiction, and depression to name a few. More research is needed and getting psychedelics into clinical trials is really the next step.

Two companies on the verge of a merger are looking to push clinical research forward in both areas. Enveric Biosciences (NASDAQ: ENVB) is a pioneer in cannabinoid research that recently announced a Phase 1/2 trial focused on CBD as a complementary treatment for recurrent cases of the devastating brain cancer glioblastoma (GBM). Enveric also recently announced a definitive agreement to acquire and combine with MagicMed Industries, a leader in the research and development of novel derivative psychedelic molecules designed for clinical use. The combination of the two companies has the potential to greatly advance pharmaceutical development in both sectors.

Clinical Trial

Enveric’s clinical trial has been approved by the Israeli Ministry of Health and will be conducted at the Davidoff Institute of Oncology, Rabin Medical Center, in Israel under Principal Investigator Dr. Tali Siegal. Israel has long been a global leader in cannabis research with the backing of the federal government, and the country continues to push the boundaries of our knowledge of the plant and its benefits.

GBM is the most common and lethal form of cancer affecting the central nervous system. Five year survival rates for patients with the disease are very poor, with about 5% surviving through that time and the average length of survival less than two years. Despite much research over the last few decades, these rates remain largely unchanged.

Enveric is studying the combination of its lead synthetic CBD candidate, EV101, with two currently accepted forms of treatment for GBM. Preclinical data supports the idea of the combined treatments, which suggest that CBD may improve the efficacy of chemo- or immuno-therapies while potentially allowing for lower doses of chemotherapeutic agents.

Glioblastoma tumors express CB2 receptors, which are the channels through which CBD and other cannabinoids are thought to exert their anti-cancer effects. Research indicates CBD may induce apoptosis, or cell death, in cancer cells. The results of Enveric’s Phase 1/2 trial could greatly further the understanding of these mechanisms and ideally improve outcomes for GBM patients.

The Combined Company

MagicMed has established a growing library, called the Psybrary, of novel compounds based on or derived from psychedelic molecules such as psilocybin and DMT. The company’s approach is to create patentable drug candidates that enhance the therapeutic effects of the naturally occurring molecules. MagicMed’s expertise lies in research and development, and its business model is to sell or license these drug candidates to pharmaceutical companies, like Enveric, with the capabilities to conduct clinical trials.

With the pending acquisition, the combined companies would be able to keep the whole process, from drug discovery and molecule development through clinical trials and drug approval, under one roof. The hope is to advance psychedelic therapies and research into the mainstream and, of course, gain approvals for drug treatments of major indications like anxiety, PTSD, and depression. The fact that Enveric is listed on the NASDAQ and has clinical trial experience should only work to the benefit of achieving those goals, both in terms of access to capital for development and more generally the acceptance of psychedelic research in the investment community.

Once the deal is finalized, some members of the MagicMed executive team will assume their existing roles in the new version of Enveric Biosciences. CEO Dr. Joseph Tucker will become CEO of Enveric, with current Enveric CEO David Johnson becoming the Executive Chairman. Meanwhile, MagicMed CSO Dr. Peter Facchini and CTO Dr. Jillian Hagel will be named to the same positions in the new company.

The Takeaway

Investors interested in early mover companies in emerging health care sectors may want to track Enveric Biosciences’ development. Upcoming inflection points include the GBM trial, the finalization of the merger between MagicMed and Enveric, and the further development of potential psychedelic therapies. The combined capabilities of the two companies could serve to greatly enhance our understanding of both cannabis and psychedelic science after decades of neglect. Stay tuned.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

VANCOUVER, British Columbia, July 22, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to highlight the continued success of the Health Canada-approved NeuroCatch Platform (“NeuroCatch”) in use at its Integrated Rehab and Performance Ltd. (“IRP”) clinic in Victoria, BC. IRP has been an early adopter of NeuroCatch’s advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020. NeuroCatch continues to differentiate IRP from other rehabilitation clinics, along with its unique focus on patients from the Canadian Armed Forces, the Royal Canadian Mounted Police and various first responder organizations.

NeuroCatch is expected to remain a key part of IRP’s service offering as Ketamine One expands its network to new veteran-centric markets across Canada. Unique service offerings such as NeuroCatch help Ketamine One’s clinicians create more tailored treatment plans for patients, which can increase their effectiveness over time. Platforms like NeuroCatch are also significant as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy. Psychedelics-focused research, a growing network of medical clinics, a broad suite of patient treatment options and leading technologies including digital therapeutics are all being brought together to create a unique mental health platform under Ketamine One.

NeuroCatch:

In 2019, Health Canada approved the NeuroCatch Platform a class II medical device developed by HealthTech Connex Inc. that conducts a rapid 6-minute scan to measure and report on cognitive brain function. It is an easy-to-use, objective, rapid neuro-physiological brain function assessment system, that provides healthcare practitioners with objective measurements of specific brain functions: auditory sensation; basic attention and cognitive processing. Researchers and clinicians use this technology to gain insight into a range of common neurological conditions, including concussion and brain injury; dementia and neurological disease; post-traumatic stress disorder and mental health; and brain performance and human optimization.

Aside from its relationship with IRP, NeuroCatch is currently also collaborating or partnered with a long list of third parties including but not limited to Alberta Children’s Hospital, CAA Hockey, Canadian Space Agency, Equinox Integrative Wellness, Helius Medical Technologies, Kids Brain Health Network, Mayo Clinic, Toronto Rehabilitation Institute, University Health Network, University of Alberta, University of Calgary, University of Toronto, University of Victoria and Weill Cornell Medicine.

For more information about NeuroCatch, please visit www.neurocatch.com.

Management Commentary:

“Embracing technology is essential for improving our patients’ outcomes at IRP and giving them the best care throughout their healing and recovery processes. The use of NeuroCatch enables our staff to customize treatment plans and track improvements in brain health of our patients,” said Steven Inglefield, Founder & CEO of IRP. “Ketamine One’s continued integration of industry-leading clinics and the most advanced treatment options gives clinicians greater insights into every patient’s care, while the Company’s research assets provide the ability to stay at the forefront of breakthrough treatments and technologies,” added Mr. Inglefield.

ABOUT KETAMINE ONE

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 16 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:

KETAMINE ONE

“Adam Deffett“
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: [email protected]

Web: www.ketamine.one

Twitter: @KetamineOne

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

VANCOUVER, BC (GLOBE NEWSWIRE – June 3, 2021) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that its US-based OTC Markets listing under the symbol “OPTHF” has received approval from the Depository Trust Company (“DTC”) to make the Company’s common shares eligible to be electronically cleared and settled through DTC (“DTC Eligibility”).

DTC is a subsidiary of the Depository Trust and Clearing Corporation, a United States company that manages the electronic clearing and settlement of publicly traded companies. DTC Eligibility incorporates an electronic method of clearing securities that speeds up the receipt of stock and cash, and thus accelerates the settlement process for certain investors. DTC is a member of the U.S. Federal Reserve System, a limited-purpose trust company under New York State banking law and a registered clearing agency with the U.S. Securities and Exchange Commission.

Optimi further advises that it is nearing completion of the process to up-list to the OTCQB exchange operated by OTC Markets Group Inc. Designed for developing and entrepreneurial companies in the United States and abroad, companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. With more compliance and quality standards, the OTCQB provides investors improved visibility to enhance trading decisions. The OTCQB is recognized by the United States Securities and Exchange Commission as an established public market providing public information for analysis and value of securities.

In addition to trading in the United States, Optimi’s common shares continue to trade on the Canadian Securities Exchange under OPTI and the German Börse Frankfurt (FRA) exchange under 8BN.

Michael Stier, CEO of Optimi notes, “Today’s news is an important milestone towards broadening our market presence across the United States as we engage with this significant shareholder audience. Listing on the OTCQB will provide heightened transparency and visibility to the investment community. DTC eligibility allows current and prospective shareholders of Optimi a reliable, cost-efficient, and timely method for clearing and settlement of our common shares. Overall, today’s news positions Optimi to engage with confidence, purpose and consideration more meaningfully with current and future investors.

On Behalf of the Board of Directors, Optimi Health Corp.

Mike Stier
President, Chief Executive Officer and Director

ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:
Investor Relations
Email: [email protected]
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS
This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

VANCOUVER, BC, May 17, 2021 /CNW/ – Filament Ventures Corp. (“Filament” or the “Company”), an exclusively-natural psychedelic drug discovery and extraction company, is pleased to announce that it has entered into an agreement with Echelon Wealth Partners Inc. and Canaccord Genuity Corp. (together, the “Co-Lead Agents”) to sell, by way of a private placement on a best efforts basis, up to that number of subscription receipts of the Company (the “Subscription Receipts”) at a price of C$0.40 – C$0.50 per Subscription Receipt (the “Issue Price”) to raise aggregate gross proceeds of up to C$10,000,000 (the “Offering”).

Each Subscription Receipt will be converted into one unit of the Company (a “Unit”) upon satisfaction of certain escrow release conditions (the “Escrow Release Conditions”). The Escrow Release Conditions shall be in a customary form and substance commensurate with industry norms and pursuant to the terms of a subscription receipt agreement to be entered into between the Company, Co-Lead Agents and Canadian trust company as subscription receipt agent.

Each Unit will be comprised of one common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant (each whole warrant, a “Warrant”), pursuant to the Amalgamation (as described below). Each Warrant shall be exercisable to acquire one Common Share at an exercise price that is 50% greater than the Issue Price for a period of 24 months from the date the Escrow Release Conditions are satisfied.

The Company has entered into a letter of intent with 1287396 BC Ltd. (the “Shell”) to complete a proposed amalgamation (the “Amalgamation”) between the Company and the Shell in conjunction with the Offering. The closing of the Offering is subject to, among other customary conditions, the Company entering into a definitive agreement with the Shell with respect to the Amalgamation.

The common shares of the issuer resulting (the “Resulting Issuer Shares”) from the Amalgamation, which will be named Filament Health Corp., are expected to be listed on the NEO Exchange (the “Exchange”). The Company submitted its initial listing application to the Exchange on April 23, 2021 and has reserved the ticker symbol “FH” in connection therewith.

The net proceeds of the Offering will be used for clinical trials, research and development, intellectual property initiatives, working capital and other general corporate purposes.

The Co-Lead Agents have been granted an option, exercisable at any time prior to 48 hours before closing of the Offering, to purchase up to an additional 15% of the number of Subscription Receipts sold pursuant to the Offering. The Company has agreed to pay the Co-Lead Agents (i) a cash commission equal to 6.0% of the gross proceeds of the Offering; and (ii) warrants exercisable for a period of 24 months from the date the Resulting Issuer Shares are listed on the Exchange to acquire that number of Resulting Issuer Shares equal to 6.0% of the number of Subscription Receipts sold pursuant to the Offering at an exercise price equal to the Issue Price (subject to adjustment in connection with the definitive terms of the Amalgamation).Â

ABOUT FILAMENT HEALTH

Filament is an exclusively-natural psychedelic drug discovery and extraction company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament believes measurable and efficacious medicines will be a catalyst to addressing many of the world’s mental health problems and that natural psychedelics provide an optimal option for widespread adoption of these substances. Filament engages in natural extraction technology and commercialization, utilizing its intellectual property portfolio, in-house good manufacturing practices and a Health Canada psilocybin Dealer’s License. Filament is headquartered in Vancouver, British Columbia.

Learn more at www.filament.health and get the latest updates via Filament’s newsletter and LinkedIn page.

DISCLAIMER

The proposed terms and conditions relating to the Offering and summarized herein are provided for discussion purposes only and do not constitute an offer, agreement or commitment by the Company to issue or sell any securities.

FORWARD LOOKING INFORMATION

Certain statements and information contained herein may constitute “forward-looking statements” and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning the completion of the Offering and Amalgamation; the approval of the Exchange; the number and Issuer Price of Subscription Receipts to be sold by Filament and the expected use of proceeds from the Offering. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Psychedelics have become one of the most promising classes of drugs in a generation, as well as an exciting new industry for investors. Despite their resurgence among researchers and investors, psychedelics have been used for thousands of years before they were criminalized in the 1970s in the United States and around the world.

Let’s take a look at the rich history of psychedelics over thousands of years, the renaissance that has emerged over the past few years and how Tryp Therapeutics (CSE: TRYP, OTCQB: TRYPF) is positioning itself to unlock value through its PFN platform and recent patent filings.

A Brief History of Psychedelics

Psychedelics have a long history that began as early as 4,000 B.C. E. where cave paintings were found in Northern Africa and Europe. In 3,700 to 3,660 B.C.E., there’s evidence that peyote was used in ceremonies by indigenous cultures in the Americas. The Aztec’s may have consumed mushrooms, known as the “flash of the Gods” between 1300 and 1521 C.E. while Catholic texts from Europe in 1500 C.E. refer to peyote use as “witchcraft”.

Modern science began in the 1900s with the isolation of mescaline and ibogaine in Europe. Synthetics emerged soon after with the invention of MDMA in 1912 and LSD in 1938. Psilocybin was discovered by Albert Hoffman in 1958 and Calvin Stevens synthesized ketamine in 1962, which ushered in the modern era of psychedelics. Of course, these drugs were regulated around the world between 1962 and 1971, creating a prohibition era.

The psychedelic renaissance began after 1971 as researchers began to discover the potential for psychedelics to treat a range of different medical conditions. After widespread cannabis legalization in the early 2010s, the movement to decriminalize psychedelics—especially for research and medical use—picked up steam. The emergence of funding from venture capital investors helped finance large-scale clinical trials that finally tipped the scale in the 2020s.

Click here to learn more about investing in Tryp Therapeutics

Bringing Psychedelics to Medicine

A growing number of private and public companies have emerged in the late 2010s and early 2020s to develop and commercialize psychedelic treatments for medical conditions. In particular, psychiatric conditions like major depressive disorder and anxiety seem to be greatly enhanced through psychedelic treatments. The breakthroughs have been strong enough to secure Breakthrough Therapy Status for several programs from the U.S. FDA.

Tryp Therapeutics (CSE: TRYP, OTCQB:TRYPF) is a pharmaceutical company with a psilocybin-for-neuropsychiatric disorders, or PFN, platform. By developing novel synthetic psilocybin, the company aims to power a new class of drugs for the treatment of certain neuropsychiatric disorders. The company’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome with few effective treatments and no cure, and of eating disorders.

The company recently announced that it submitted a provisional patent to improve how psychedelics are administered across a broad range of conditions. In particular, the proprietary methods represent the foundational elements of a comprehensive medical treatment program that the company is developing.  It also marks the first of many patent filings to enhance the effectiveness of psychedelics and build a valuable patent portfolio.

Click here to learn more about investing in Tryp Therapeutics

Looking Ahead

Psychedelics have a rich history spanning thousands of years. While the class of drugs has been restricted for therapeutic use since the 1970s, the psychedelic renaissance has sparked renewed interest and a range of companies seeking to bring therapeutics to market.

Tryp Therapeutics (CSE: TRYP) represents one of the most promising companies in the space with its PFN platform and its clinical research programs for fibromyalgia and eating disorders. With its recent provisional patent filing, the company is making core improvements to the formulation, delivery and dosing of active ingredients, helping to differentiate itself from other companies in the space. Investors may want to take a closer look at the stock given these dynamics and its upcoming clinical catalysts.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Die Psybrary von MagicMed ist eine bemerkenswerte und beeindruckende Leistung, die mehr als geschätzten 125 Millionen Derivaten bis zu deren Patenterteilung Patentschutz bieten könnte. Während 125 Millionen Derivate eine große Zahl ist, sollten dabei zwei Dinge klargestellt werden. Erstens bedeutet diese Zahl nicht, dass das Unternehmen eine kleine Armee von Wissenschaftlern weggesperrt hat, um 125 Millionen verschiedener Moleküle zu synthetisieren. Zweitens hat MagicMed auch nicht 125 Millionen separate und individuelle Patente zum Schutz jedes einzelnen Moleküls angemeldet. Tatsächlich hat MagicMed etwas mehr als 200 der potenziellen Moleküle synthetisiert, die in der Psybrary enthalten sind. Durch das Einreichen von 12 vorläufigen Patenten hat MagicMed den Prozess gestartet, um den Schutz einiger der Moleküle in der Psybrary zu gewährleisten. Eine vorläufige Patentanmeldung ermöglicht einen früheren Anmeldetag zu geringeren Kosten und dient als 12-monatiger Platzhalter, falls sich ein Unternehmen später für einen vollständigen Patentschutz entscheidet. Diese vorläufigen Patente können zu einem späteren Zeitpunkt in nicht vorläufige Patentanmeldungen umgewandelt werden und würden, falls sie erteilt werden, Patentschutz gewähren, der durch den Patentkooperationsvertrag (PCT) international anerkannt ist. Aber was bedeutet das eigentlich? Es kann nützlich sein, sich diese Patente als kompliziert und rechtlich begründet vorzustellen und die eigenen Abenteuergeschichten zu wählen.

Die Struktur eines Patents

Patente sind wie Geschichten auf bestimmte Weise organisiert und stützen sich auf bestimmte Abschnitte, um die Geschichte einer Erfindung zu erzählen. Beide beginnen mit einem Titel und brauchen diesen Titel, um dem Leser eine Vorstellung davon zu geben, worüber er lesen wird. Während eine Geschichte Seiten enthält, auf denen der Autor, der Herausgeber und etwaige Anerkennungen vorgestellt werden, enthält ein Patent Abschnitte, in denen die Erfinder und das Unternehmen, das möglicherweise Rechte an der Erfindung hat sowie frühere oder verwandte Patentanmeldungen aufgeführt sind. Während Literaturstudien die Abschnitte einer Geschichte in einem Diagramm darlegen, erzählt die Struktur eines Patents eine Geschichte, indem es beschreibt, in welchem ​​Sektor oder in welcher Branche eine Erfindung tätig ist, indem die Erfindung zusammengefasst und anschließend eine detaillierte Beschreibung der betreffenden Erfindung bereitgestellt wird. Dies schafft eine wirklich aufregende Geschichte für Menschen, die sich mit Patenten und geistigem Eigentum auskennen. Die Parallele zwischen Geschichten mit frei wählbarem Ende und und Patenten findet sich im Anspruchsabschnitt eines Patents, welcher der wichtigste Abschnitt ist. Wenn ein bestimmtes Molekül wie das Ende einer Geschichte ist, sind die Ansprüche die Aussagen, die den Umfang und den Prozess definieren, die zum Ende hinführen.

Klicken Sie hier, um eine Investorenpräsentation und Unternehmensaktualisierungen zu erhalten

Die Struktur eines Anspruchs

Der erste Teil des Anspruchs, die Präambel, definiert den Umfang der Erfindung und beschreibt, zu welcher Kategorie eine Erfindung gehört: ein physikalischer Gegenstand (eine Vorrichtung oder ein Molekül), ein Verfahren oder eine Art etwas zu tun (wie etwas hergestellt wird) oder eine neuartige Art etwas zu verwenden (häufig zu sehen, wenn Medikamente für neue Indikationen verwendet werden). Der Präambel folgt eine von drei Übergangssätzen: “umfassend”, “bestehend aus” und “wesentlich bestehend aus” und dann der Hauptteil des Anspruchs. Die Übergangssätze sind entscheidend für die Festlegung, wie eng oder breit der Umfang eines Anspruchs sein wird. Die Verwendung des Übergangssatzes “umfassend” ermöglicht es, etwas flexible Parameter im Hauptteil des Anspruchs zu skizzieren. Während “umfassend” etwas flexibel ist, zeigt “bestehend aus” an, dass die Erfindung auf einen spezifischen, engen Satz von Parametern beschränkt ist. Schließlich bedeutet “wesentlich bestehend aus”, dass eine Erfindung durch bestimmte Parameter begrenzt ist oder zusätzliche Komponenten vorhanden sein können, die aber die Natur der Erfindung nicht wesentlich verändern. Wenn ein Anspruch den Übergangssatz “umfassend” verwendet, liefert er genügend Details, um eine grobe Schätzung der Erfindung zu geben, und kann als unabhängiger Anspruch betrachtet werden. Ansprüche, die “bestehend aus” verwenden, definieren eine Erfindung häufig nicht vollständig, verweisen auf einen früheren unabhängigen Anspruch und werden als abhängig angesehen. Unabhängige Ansprüche bieten in Zusammenarbeit eine breite Definition, die dann durch nachfolgende abhängige Ansprüche unterstützt und verfeinert wird.

Wählen Sie Ihr eigenes Ende

Nachdem Sie eine Vorstellung von der Struktur eines Patents und den darin enthaltenen Ansprüchen haben, können wir die Analogie eines Romans mit frei wählbarem Ende erneut betrachten. In vielen Geschichten wird einem Helden eine etwas vage Aufgabe zugewiesen, die „Suche“, die unter anderem durch „Ehre“, „Gefahr“ und „jemanden, der gerettet werden muss“ gekennzeichnet ist. Diese Suche ähnelt einem unabhängigen Anspruch. Sie enthält einige grobe Parameter, die dem Bestreben einen gewissen Spielraum bieten, aber insgesamt fehlen Einzelheiten. Nachdem dem Helden eine Aufgabe zugewiesen wurde, trifft er normalerweise auf Nebencharaktere, die jeweils ihre eigene Meinung zu „Ehre“, „Gefahr“ und „jemandem, der gerettet werden muss“ haben, was den Umfang der Aufgabe weiter definiert. Zum Beispiel könnte “Ehre” bedeuten, ein Dorf zu retten oder ein persönliches Opfer durch den Helden zu bringen, “Gefahr” könnte bedeuten, eine Naturkatastrophe zu verhindern oder ein gefährliches Monster zu töten, und “jemand, der gerettet werden muss” könnte buchstäblich jeder sein. In jedem Fall ähneln diese Zeichen und die von ihnen bereitgestellte Struktur abhängigen Ansprüchen. Abhängig von der groben Definition einer Aufgabe, welchen Nebencharakteren der Held begegnet und welche Meinungen sie zu den Ereignissen der Aufgabe haben, wird der Held mit einer Vielzahl von Reisen konfrontiert, die alle als “Aufgabe“ betrachtet werden können. Dieselbe Variabilität spiegelt sich in der Definition des Umfangs einer Erfindung und deren möglichen Derivaten wider.

Diese Variabilität gilt insbesondere für Arzneimittel mit einer ähnlichen Kernstruktur. Benzoxazolderivate bilden eine vielfältige Gruppe von Arzneimitteln mit medizinischen Eigenschaften, die von der Abtötung von Bakterien bis zur Schmerzlinderung reichen und alle auf einem einfacheren Molekül, Benzoxazol, basieren. Eine Kernstruktur kann chemisch verändert werden, sodass bestimmte chemische Gruppen an einem bestimmten Ort hinzugefügt werden. Ein Molekül und die verschiedenen chemischen Gruppen, die hinzugefügt werden, sind wie die Aufgabe und ihre vagen Anforderungen. Die chemischen Gruppen können viele verschiedene und verwandte Strukturen enthalten, sind durch die Ansprüche definiert und legen fest, welche Derivate zu einer Erfindung gehören. Boxazomycin A und B sind zwei Arten von Antibiotika mit Benzoxazolderivaten, die durch Modifikation einer einzelnen chemischen Gruppe hergestellt werden (innerhalb des roten Kreises mit „R“ bezeichnet). Während dieses Beispiel einer Gruppe mit zwei Möglichkeiten und zwei möglichen Derivaten einfach ist, können einigen Molekülen mehrere Gruppen hinzugefügt werden und durch Ansprüche mit 100 oder 1000 akzeptablen Alternativen begrenzt werden. Ansprüche, die den Umfang einer Erfindung unter Verwendung verwandter Modifikationen erweitern, sind als Markush-Ansprüche bekannt und in der pharmazeutischen Industrie üblich. Ein Kernmolekül mit 3 R-Gruppen mit jeweils 100 möglichen Modifikationen erzeugt eine Million verschiedene Kombinationen (100 * 100 * 100). Verschiedene psychedelische Strukturen mit jeweils zahlreichen möglichen Modifikationen ermöglichen es MagicMed, verschiedene Patente einzureichen und Millionen verschiedener Moleküle zu schützen. Ähnlich wie eine Bibliothek, die ihre Büchersammlung erweitert, wird MagicMed sein geistiges Eigentum weiter ausbauen, sein Portfolio um weitere Patente erweitern und die Psybrary erweitern, um noch mehr patentgeschützte Moleküle aufzunehmen.

Klicken Sie hier, um die Investorenpräsentation und Unternehmensaktualisierungen zu erhalten

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.